Contribute Try STAT+ Today

Last November and then again in February, Bristol Myers Squibb said its oral drug designed to treat psoriasis differently from currently approved medicines had achieved the goals of large Phase 3 clinical trials.

On Friday, the actual data from those two studies were presented publicly for the first time at the annual meeting of the American Academy of Dermatology. The Bristol drug, called deucravacitinib, proved more effective at clearing the chronic skin disease — numerically and statistically — compared to a placebo and a competing drug from Amgen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Adam, how is 59% PASI 75 for deucravacitinib “less effective” than 60% PASI 75 for Humira? This appears to me to be an oral non-biologic with efficacy of 1st gen biologics, at least for psoriasis. And there are very real safety issues with those anti-TNF biologics like Humira – malignancies specifically are a concern.
    the overall link to JAK inhibitors in this piece feels overdone. This is not a JAK, though it’s mechanism is tangentially related.
    To me, considering the multiple potential indications beyond psoriasis, 4 billion in annual sales feels conservative. This treatment will knock out Otezla and be in front of TNF inhibitors. If efficacy is sustained over time (which TNFs are notorious for failing to do), who knows what the ceiling is, as long as the safety profile holds.
    No, I do not work for or with BMS, nor am I a stock holder (except maybe some percentage of BMS in a life science index fund).

Comments are closed.